Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Apix Biosciences is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units, indicating that the company's pending research covers different specialized fields within the sector. The involvement of multiple art units suggests a technical footprint that spans several areas of review.
Prosecution is handled by a pair of distinct examiners. WILLIAMS, EMMALEE RAE is the busiest examiner, responsible for 1 pending office action. With two distinct examiners for the pending office actions, each application is being reviewed independently. This means that the practitioner must manage separate prosecution tracks, each tailored to the specific examiner and art unit involved. The distribution among the 2 distinct examiners ensures that the outcome of one pending office action does not necessarily influence the other.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIAMS, EMMALEE RAE | 1 | 25.0% | +100.0% |
| DIVIESTI, KARLA ISOBEL | 1 | 3.2% | +16.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693323 | PROANTHOCYANIDINS (CONDENSED TANNINS) AS INVERTEBRATE NUTRIENT | DIVIESTI, KARLA ISOBEL | 36d |
| 18710789 | STEROL PRODUCTION IN YEAST | WILLIAMS, EMMALEE RAE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693323 | PROANTHOCYANIDINS (CONDENSED TANNINS) AS INVERTEBRATE NUTRIENT | DIVIESTI, KARLA ISOBEL | 36d |
| 18710789 | STEROL PRODUCTION IN YEAST | WILLIAMS, EMMALEE RAE | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710789 | STEROL PRODUCTION IN YEAST | WILLIAMS, EMMALEE RAE | 1653 | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18693323 | PROANTHOCYANIDINS (CONDENSED TANNINS) AS INVERTEBRATE NUTRIENT | DIVIESTI, KARLA ISOBEL | 1792 | §103 | Final Rejection | 36d | Pending | Mar 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApix Biosciences has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Emmalee Rae Williams has the most, with 1 of Apix Biosciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.